LARUSSA, Tiziana
 Distribuzione geografica
Continente #
NA - Nord America 1.150
AS - Asia 742
EU - Europa 686
SA - Sud America 132
OC - Oceania 11
AF - Africa 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 2.737
Nazione #
US - Stati Uniti d'America 1.092
SG - Singapore 291
IT - Italia 226
CN - Cina 186
DE - Germania 133
IN - India 117
BR - Brasile 106
GB - Regno Unito 102
FI - Finlandia 69
SE - Svezia 56
CA - Canada 44
IR - Iran 38
VN - Vietnam 35
NL - Olanda 24
TR - Turchia 18
RU - Federazione Russa 13
TW - Taiwan 11
AU - Australia 10
PL - Polonia 10
AR - Argentina 9
BD - Bangladesh 8
MX - Messico 8
UA - Ucraina 8
FR - Francia 7
HK - Hong Kong 7
RO - Romania 6
ES - Italia 5
CL - Cile 4
EC - Ecuador 4
EU - Europa 4
ID - Indonesia 4
IQ - Iraq 4
PY - Paraguay 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
AT - Austria 3
CZ - Repubblica Ceca 3
IL - Israele 3
JP - Giappone 3
LT - Lituania 3
PH - Filippine 3
SA - Arabia Saudita 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AL - Albania 2
BE - Belgio 2
CH - Svizzera 2
CU - Cuba 2
EG - Egitto 2
HU - Ungheria 2
MA - Marocco 2
PK - Pakistan 2
UY - Uruguay 2
BB - Barbados 1
BG - Bulgaria 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
GF - Guiana Francese 1
GR - Grecia 1
HN - Honduras 1
JM - Giamaica 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
MD - Moldavia 1
MG - Madagascar 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RS - Serbia 1
VE - Venezuela 1
Totale 2.737
Città #
Chandler 152
Singapore 125
Munich 114
Dallas 106
Chicago 90
London 86
Santa Clara 82
Hefei 79
Bengaluru 77
Lawrence 68
Princeton 68
Milan 66
Ashburn 47
Helsinki 47
Wilmington 41
Ottawa 30
Catanzaro 28
Des Moines 21
Redwood City 19
Mumbai 17
São Paulo 17
Turku 14
Beijing 12
Ho Chi Minh City 12
Los Angeles 12
Mendicino 12
Shanghai 11
Guangzhou 10
Hanoi 9
Istanbul 9
Praia A Mare 9
Boardman 8
Phoenix 8
Rome 8
Collegeville 7
New York 7
Pune 7
Tehran 7
Cittanova 6
Redmond 6
The Dalles 6
Warsaw 6
Brooklyn 5
Chennai 5
Hanover 5
Hong Kong 5
Jyväskylä 5
Montreal 5
Norwalk 5
San Francisco 5
Shenzhen 5
Boston 4
Clearwater 4
Curitiba 4
Horia 4
Rio de Janeiro 4
Selargius 4
Taipei 4
Bade District 3
Bari 3
Benevento 3
Bratislava 3
Charlotte 3
Council Bluffs 3
Dhaka 3
Jiaxing 3
Kahramanmaraş 3
Miguel Hidalgo 3
Nanjing 3
Naples 3
Paris 3
Rende 3
Riyadh 3
San Juan 3
Stockholm 3
São Bernardo do Campo 3
Wuxi 3
Zabki 3
Ankara 2
Ann Arbor 2
Atlanta 2
Baghdad 2
Belo Horizonte 2
Biên Hòa 2
Brasília 2
Buffalo 2
Bungarribee 2
Calumpit 2
Campinas 2
Cape Town 2
Capurso 2
Casablanca 2
Castel Campagnano 2
Chelsea 2
Chittagong 2
Columbus 2
Da Nang 2
Encarnación 2
Esslingen am Neckar 2
Frankfurt am Main 2
Totale 1.743
Nome #
Adverse drug reactions during biologic therapy in inflammatory disease: real life data from the pharmacovigilance project in the Calabria region 230
Dietary polyphenolsand non-alcoholic fatty liver disease 87
A Framework for Patient Data Management and Analysis in Randomised Clinical Trials 72
Efficacy of Mediterranean diet and antioxidants in overweight patients with non-alcoholic fatty liver disease. 64
Barriers And Facilitators In Conducting Clinical Trials In Inflammatory Bowel Disease: A Monocentric Italian Survey. 63
COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey 62
The role of gluten-free diet in nonalcoholic fatty liver disease development 61
Anxiety and Gastrointestinal Symptoms Related to COVID-19 during Italian Lockdown 59
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab 55
Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy 55
Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview 49
Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. 48
Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. 48
SARS-CoV-2 Spread Dynamics in Italy: The Calabria Experience 48
Oleuropein Decreases Cyclooxygenase-2 and Interleukin-17 Expression and Attenuates Inflammatory Damage in Colonic Samples from Ulcerative Colitis Patients 46
Effect of selective cyclooxygenase (Cox)-2 Inhibition and proton pump inhibitors (PPI) therapy on TH1 immune response in human gastric mucosa 45
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers 44
Enhanced expression of indole amine 2,3-dioxygenase (IDO) in Helicobacter pylori-infected human gastric muciosa downregulates interleukin (IL)-17 and upregulates IL-4 production. 42
Enhanced expression of indoleamine 2,3-dioxygenase (IDO) in Helicobacter pylori-infected human gastric mucosa modulates TH1/TH2 patway and interleukin (IL)-17 production. 42
Decreased circulating interleukin-33 concentration in Helicobacter pylori-infected patients with peptic ulcer: Evaluation of its association with a cytokine gene polymorphism, gender of patients and bacterial virulence factor CagA 42
Gut microbiota and non-alcoholic fatty liver disease 42
Helicobacter pylori and T Helper Cells: Mechanisms of Immune Escape and Tolerance 40
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 39
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 39
Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers 39
Bone mineralization in celiac disease 38
Diminished circulating concentration of interleukin-35 in Helicobacter pylori-infected patients with peptic ulcer: Its association with FOXP3 gene polymorphism, bacterial virulence factor CagA, and gender of patients 37
Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study 37
Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial 37
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers 35
Oleuropein decreases interleukin-17 and attenuates inflammatory damage in colonic mucosa from ulcerative colitis patients 34
Self-Prescribed Dietary Restrictions are Common in Inflammatory Bowel Disease Patients and Are Associated with Low Bone Mineralization 34
Reduced bone mineral density is frequent in treated adult coeliac disease not with standing complete normalization of duodenal lesions. 34
Downregulation of Interleukin- (IL-) 17 through Enhanced Indoleamine 2,3-Dioxygenase (IDO) Induction by Curcumin: A Potential Mechanism of Tolerance towards Helicobacter pylori 34
Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers 33
Very low vitamin D level is an independent risk factor for bone demineralization in IBD patients 33
Effect of selective cyclooxygenase (COX)-2 inhibition and proton pump inhibitors (PPI) therapy on TH1 immune response in human gastric mucosa 33
Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients 32
Enhanced activation of cyclooxygenase-2 down-regulates Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa 32
Multifaceted pathogenesis of liver steatosis in inflammatory bowel disease: A systematic review 32
Crohn disease: Identification, diagnosis, and clinical management. 31
Potential role of fecal gluten immunogenic peptides to assess dietary compliance in celiac patients 30
Normal Bone Mineral Density Associates with Duodenal Mucosa Healing in Adult Patients with Celiac Disease on a Gluten-Free Diet 29
Living with inflammatory bowel diseases: patients’ perceptions and unmet needs from a single-center Italian survey 29
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to standard pharmeceutical treatment: a double-blind, randomized, placebo-controlled study 29
The protective effects of resveratrol on ulcerative colitis via changing the profile of Nrf2 and IL-1β protein 29
Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver disease 29
SURVEY ON ALCOHOL CONSUMPTION IN A GASTROENTEROLOGY OUTPATIENT CENTER IN SOUTHERN ITALY 28
Survey on alcohol consumption in a gastroenetrology outpatient center in southern Italy. 28
Epidemiology of Helicobacter pylori infection: the Sorbo San Basile study. 27
Liver Cirrhosis Complications Management At The Emergency Department 27
Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed. 27
Enhanced Expression of Indoleamine 2,3-Dioxygenase (IDO) in Helicobacter pylori-Infected Human Gastric Mucosa Modulates TH1/Th2 Pathway and Interleukin (IL)-17 Production. 26
T cell subsets play an important role in the determination of the clinical outcome of Helicobacter pylori infection 26
Increased Indoleamine 2, 3-Dioxygenase expression modulates Th1/Th17/Th22 and Treg pathway in humans with Helicobacter Pylori-Infected gastric mucosa 26
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 25
High prevalence of polymorphism and low activity of thiopurine methiltransferase in patients with inflammatory bowel disease. 25
High Exposure, Spontaneous Clearance, and Low Incidence of Active Helicobacter pylori Infection: The Sorbo San Basile Study 25
Short-term Therapy with Celecoxib and Lansoprazole Modulates Th1/Th2 Immune Response in Human Gastric Mucosa 24
Potential role of nutraceutical compounds in inflammatory bowel disease 24
Use of Complementary and Alternative Medicine by Patients with Irritable Bowel Syndrome According to the Roma IV Criteria: A Single-Center Italian Survey 23
No evidence of circulating autoantibodies against osteoprotegerin in treated celiac patients with low bone mineral density. 22
Toll-like receptor 2: An important immunomodulatory molecule during Helicobacter pylori infection 22
Trends and characteristics associated with dietary triggers and psychological distress in patients with irritable bowel syndrome: a cross-sectional study 21
Enhanced expression of indoleamine 2,3-dioxygenase in Helicobacter pylori-infected human gastric mucosa modulates Th1/Th2 pathway and interleukin 17 production 21
Vitamin D down-regulates the expression of some Th17 cell-related cytokines, key inflammatory chemokines, and chemokine receptors in experimental autoimmune encephalomyelitis 21
The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study 21
Nutrigenomics and Nutrigenetics in Metabolic- (Dysfunction) Associated Fatty Liver Disease: Novel Insights and Future Perspectives 21
Liver steatosis in celiac disease: the open door 20
Enhanced expression of indoleamine 2,3-dioxygenase in Helicobacter pylori-infected human gastric mucosa modulates Th1/Th2 pathway and interleukin 17 production 20
No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease 20
OLEUROPEIN EXERTS ANTIOXIDANT ACTIVITY AND REDUCES THE EXPRESSION OF COX-2 AND PROINFLAMMATORY CYTOKINES IN CACO-2 CELLS AND COLONIC MUCOSA FROM ULCERATIVE COLITIS PATIENTS 19
From Pre- and Probiotics to Post-Biotics: A Narrative Review. 18
High prevalence of polymorphism and low activity of thiopurine methyltransferase in patients with inflammatory bowel disease. 17
Refractory ulcerative colitis complicated by cytomegalovirus infection successfully treated with valganciclovir 17
Olive Tree Biophenols in Inflammatory Bowel Disease: When Bitter is Better 15
Beneficial effects of coffee in non-alcoholic fatty liver disease: a narrative review 13
Totale 2.851
Categoria #
all - tutte 32.845
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.845


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021116 0 0 0 16 17 13 10 19 32 7 2 0
2021/2022258 8 7 14 49 17 4 10 48 22 26 37 16
2022/2023610 138 35 48 41 34 36 7 50 55 96 62 8
2023/2024290 69 20 25 16 10 75 6 15 27 2 9 16
2024/2025884 119 45 43 18 70 121 64 42 159 8 73 122
2025/2026557 84 185 142 146 0 0 0 0 0 0 0 0
Totale 2.851